PMID- 28815289
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20191210
IS  - 1432-1173 (Electronic)
IS  - 0017-8470 (Linking)
VI  - 68
IP  - 9
DP  - 2017 Sep
TI  - [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].
PG  - 727-739
LID - 10.1007/s00105-017-4018-0 [doi]
AB  - Primary cutaneous large B‑cell lymphomas (PCBLT), EBV-positive large B‑cell 
      lymphomas, not otherwise specified (EBV+ DLBCL, NOS), and primary cutaneous 
      intravascular large B‑cell lymphomas (PCIVLBL) are recognized as cutaneous 
      lymphomas with intermediate to poor prognosis. Differentiation from indolent 
      B‑cell lymphomas or other pathologies of the skin can be complex, both clinically 
      and histologically, but vital for the outcome of the patient. The combination of 
      immunotherapy and polychemotherapy regimens, such as R‑CHOP, has led to 
      significant improvements in prognosis, especially in diffuse large B‑cell 
      lymphomas. Therapeutic decisions need to be individually made for each patient, 
      ideally within an interdisciplinary tumor conference. Immunosenescence may be an 
      important factor in the pathogenesis of EBV+ DLBCL, NOS in elderly individuals. 
      Their prognosis is less favorable than that of patients with EBV-negative PCBLT, 
      whereby this has been observed particularly in elderly patients. One third of 
      patients with PCIVLBL progress to systemic disease. The occurrence of nodal 
      manifestation is rarely observed. Symptoms may vary depending on the organ system 
      involved. Currently there are no evidence-based therapy recommendations due to 
      the rarity of the disease. EBV-positive mucocutaneous ulcer is a new provisional 
      category in the current WHO classification for lymphoid neoplasms. It has been 
      segregated from EBV+ DLBCL, NOS due to its self-limiting course and good response 
      to conservative therapy.
FAU - Lamos, C
AU  - Lamos C
AD  - Hautklinik Ludwigshafen, Klinikum der Stadt Ludwigshafen am Rhein, 
      Bremserstr. 79, 67063, Ludwigshafen, Deutschland. lamosc@klilu.de.
FAU - Dippel, E
AU  - Dippel E
AD  - Hautklinik Ludwigshafen, Klinikum der Stadt Ludwigshafen am Rhein, 
      Bremserstr. 79, 67063, Ludwigshafen, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Aggressive primar kutane B-Zell-Lymphome und neue EBV-positive Entitaten.
PL  - Germany
TA  - Hautarzt
JT  - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
JID - 0372755
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (R-CHOP protocol)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biopsy
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Epstein-Barr Virus Infections/classification/*diagnosis/pathology/therapy
MH  - Female
MH  - Guideline Adherence
MH  - Humans
MH  - Lymphoma, B-Cell/classification/*diagnosis/pathology/therapy
MH  - Lymphoma, Large B-Cell, Diffuse/classification/diagnosis/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prednisone/therapeutic use
MH  - Prognosis
MH  - Rituximab
MH  - Skin/pathology
MH  - Skin Neoplasms/classification/*diagnosis/pathology/therapy
MH  - Vincristine/therapeutic use
OTO - NOTNLM
OT  - Epstein-Barr virus
OT  - Immunosenescence
OT  - Immunotherapy
OT  - Polychemotherapy
OT  - Prognosis
EDAT- 2017/08/18 06:00
MHDA- 2019/01/03 06:00
CRDT- 2017/08/18 06:00
PHST- 2017/08/18 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
PHST- 2017/08/18 06:00 [entrez]
AID - 10.1007/s00105-017-4018-0 [pii]
AID - 10.1007/s00105-017-4018-0 [doi]
PST - ppublish
SO  - Hautarzt. 2017 Sep;68(9):727-739. doi: 10.1007/s00105-017-4018-0.